Another step forward has been made toward the enrollment of new patients in the DEEP-2 study, the phase III multicentre, randomised, open label, non-inferiority active-controlled trial aiming at comparing for the first time the efficacy of deferiprone (DFP) vs deferasirox (DFX) in paediatric patients affected […]
The DEEP project has received research funding from the European Union under the 7th Framework Programme
News | DEEP Project - Part 6
DEEP-3 at a glance: interview to Prof. Antje Neubert
DEEP-3 is a long-term observational safety study which evaluates the nature and incidence of adverse effects of deferiprone (DFP) in children and adolescents with beta-thalassaemia major by conducting a multi-centre, multi-national, observational cohort study with both retrospective (using chart review) and prospective data […]
DEEP joins Rare Disease Day in making the voice of rare diseases heard!
The 29th February, 2016 marked the ninth international Rare Disease Day coordinated by EURORDIS . The main objective of Rare Disease Day was to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives. The campaign targeted primarily the general public […]
The Italian Multiregional Thalassemia Registry: centers characteristics, services and patients’ population
Consorzio per Valutazioni Biologiche e Farmacologiche’s research activity in the pharmacological field is much diversified and it is mainly conducted in the context of national and EU level. It is focused on the development and application of innovative methodologies in clinical trials on small populations, the management […]